Company updateCNBC-TV18
Natco Pharma receives EIR from US FDA for Visakhapatnam plant
Positive+20
GreyOak summary
GreyOak has no summary for this story yet.
What it affects
- Natco PharmaNATCOPHARMPositive +20
Received FDA EIR; shares gained then fell.Rolling sentiment Negative -34
Source
Reported by CNBC-TV18
More Natco Pharma news
- Natco Pharma gets USFDA EIR for Visakhapatnam plantBusinessLine · Regulatory ·
- Buy Natco Pharma: target of Rs 1065: ICICI SecuritiesMoneycontrol · Company update ·
- Natco Pharma shares rally 9% despite weak Q2 resultsNDTV Profit · Results ·
- Natco Pharma Q2 profit drops 60.8% to ₹202.6 crBusiness Standard · Results ·
- Natco Pharma Q2 profit, revenue fall; dividend declaredCNBC-TV18 · Results ·